| 000 | 05359cam a2200409 i 4500 | ||
|---|---|---|---|
| 001 | 200454395 | ||
| 999 |
_c200454395 _d72607 |
||
| 003 | TR-AnTOB | ||
| 005 | 20241115113202.0 | ||
| 006 | m o d | ||
| 007 | cr cnuaaaau | ||
| 008 | 210621s2021 nju ob 001 0 eng | ||
| 020 |
_a9781119701071 _q(paperback) |
||
| 020 |
_z9781119701088 _q(e-book) |
||
| 020 |
_z9781119701118 _q(epub) |
||
| 040 |
_aDNLM/DLC _beng _erda _cDLC _dTR-AnTOB |
||
| 041 | 0 | _aeng | |
| 060 | 0 | 0 |
_aQV 771 _bT355 2021 |
| 096 |
_aQV771 _bT355 2021 EBK |
||
| 245 | 0 | 0 |
_aTextbook of pharmacoepidemiology / _cedited by Brian L. Strom, Sean Hennessy, Stephen E. Kimmel. |
| 250 | _aThird edition | ||
| 264 | 1 |
_aNew Jersey : _bWiley-Blackwell, _c2021. |
|
| 300 | _a1 online resource. | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 504 | _aBIBINDX | ||
| 505 | 0 | _aWhat is Pharmacoepidemiology? / Brian L. Strom -- Study Designs Available for Pharmacoepidemiologic Studies / Brian L. Strom -- Sample Size Considerations for Pharmacoepidemiologic Studies / Brian L. Strom -- Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies / Jeffrey S. Barrett -- When Should One Perform Pharmacoepidemiologic Studies? / Brian L. Strom -- Views from Academia, Industry, Regulatory Agencies, and the Legal System / Joshua J Gagne, Jerry Avorn, Nicolle M Gatto,Jingping Mo, Gerald J. Dal Pan, June Raine, Shinobu Uzu, Aaron S. Kesselheim, Kerstin N. Vokinger -- Postmarketing Spontaneous Pharmacovigilance Reporting Systems / -- Gerald J. Dal Pan, Marie Lindquist, and Kate Gelperin -- Overview of Electronic Databases in Pharmacoepidemiology / Brian L. Strom -- Encounter Databases / Tobi Gerhard, Yola Moride, Anton Pottegard, Nicole Pratt -- Electronic Health Record Databases / Daniel Horton, Harshvinder Bhullar, Francesca Cunningham, Janet Sultana B. Pharm (Hons.), and Gialuca Trifiro -- Primary Data Collection for Pharmacoepidemiology / Priscilla Velentgas -- How Should One Perform Pharmacoepidemiologic Studies? Choosing Among the Available Alternatives / Brian L. Strom -- Validity of Drug and Diagnosis Data in Pharmacoepidemiology / Mary Elizabeth Ritchey, Suzanne L West, and George Maldonado -- Assessing Causality from Case Reports / Bernard Begaud, and the late Judith K. Jones -- Molecular Pharmacoepidemiology / Christine Y Lu and Stephen E. Kimmel -- Bioethical Issues in Pharmacoepidemiologic Research / Laura E Bothwell, Annika Richterich, and Jeremy Greene -- The Use of Randomized Controlled Trials in Pharmacoepidemiology / -- Robert Reynolds, Samuel M. Lesko, Allen A. Mitchell -- Pharmacoeconomics: Economic Evaluation of Pharmaceuticals / Kevin A. Schulman -- Patient Engagement and Patient Reported Outcomes / Esi Morgan -- The Use of Meta-analysis in Pharmacoepidemiology / Jesse A. Berlin, Vrenda J Crowe, H Amy Xia, and Stephen JW Evans -- Studies of Medication Adherence / Julie Lauffenburger, Trisha Acri, and Robert Gross -- Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies / Sebastian Schneeweiss and Samy Suissa -- Special Applications of Pharmacoepidemiology / David Lee, Björn Wettermark, Christine Y. Lu, Stephen B. Soumerai, Robert T. Chen, Sharon-Lise T. Normand, Art Sedrakyan, Danica Marinac-Dabic, Daniel B. Horton, Sonia Hernandez-Diaz, Tamar Lasky, Krista F. Huybrechts, Claudia Manzo, Emil Cochino, Hanna M. Seidling, David W. Bates, Bennett Levitan, -- Rachel DiSantostefano, Scott Evans -- The Future of Pharmacoepidemiology / Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy. | |
| 520 |
_a"It was a remarkable 32 years ago that the first edition of Strom's Pharmacoepidemiology was published. The preface to that book stated that pharmacoepidemiology was a new field with a new generation of pharmacoepidemiologists arising to join the field's few pioneers. Over the ensuing 32 years, the field indeed has grown and no longer deserves to be called "new." Many of those "new generation" scientists (including two of the editors of this book) are now "middle-aged" pharmacoepidemiologists. Despite its relatively brief academic life, a short history of pharmacoepidemiology and review of its current state will set the stage for the purpose of this textbook. Pharmacoepidemiology originally arose from the union of the fields of clinical pharmacology and epidemiology. Pharmacoepidemiology studies the use of and the effects of medical products in large numbers of people and applies the methods of epidemiology to the content area of clinical pharmacology. This field represents the science underlying postmarketing medical product surveillance, studies of the effects of medical products (i.e., drugs, biologicals, devices) performed after a product has been approved for use. In recent years, pharmacoepidemiology has expanded to include many other types of studies, as well"-- _cProvided by publisher. |
||
| 650 | 2 |
_aPharmacoepidemiology _xmethods _9143489 |
|
| 655 | 0 |
_aElectronic books _2local _92032 |
|
| 700 | 1 |
_aStrom, Brian L. _eeditor _9143485 |
|
| 700 | 1 |
_aHennessy, Sean _eeditor _9143486 |
|
| 700 | 1 |
_aKimmel, Stephen E. _eeditor _9143487 |
|
| 856 |
_uhttps://onlinelibrary.wiley.com/doi/book/10.1002/9781119701101 _zOnline access link to the resource |
||
| 942 |
_2NLM _cEBK |
||